Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study

被引:92
作者
Aapro, Matti [1 ]
Leonard, Robert C.
Barnadas, Agusti
Marangolo, Maurizio
Untch, Michael
Malamos, Nikolaos
Mayordomo, Jose
Reichert, Dietmar
Luiz Pedrini, Jose
Ukarma, Lidia
Scherhag, Armin
Burger, Hans-Ulrich
机构
[1] Clin Genolier, Inst Multidisciplinaire Oncol, CH-1272 Genolier, Switzerland
关键词
D O I
10.1200/JCO.2007.11.5378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The Breast Cancer-Anemia and the Value of Erythropoietin ( BRAVE) study evaluated whether epoetin beta would improve survival in patients with metastatic breast cancer ( MBC). Patients and Methods BRAVE was an open-label, randomized, multicenter study in patients with MBC treated with anthracycline- and/or taxane-based chemotherapy. Patients ( hemoglobin [ Hb] < 12.9 g/dL) were randomly assigned ( 1: 1) to epoetin beta 30,000 U subcutaneously once weekly or control for 24 weeks. The primary efficacy variable was overall survival. Secondary efficacy outcomes included progression-free survival, transfusion- and severe anemia-free survival, Hb response, safety, and quality of life ( QoL). Results After 18 months of follow-up, 62 ( 27%) of 231 patients survived with epoetin beta therapy and 63 ( 27%) of 232 with control. No difference was detected in overall survival ( hazard ratio [ HR] = 1.07; 95% CI, 0.87 to 1.33, P =.522) or progression-free survival ( HR = 1.07; 95% CI, 0.89 to 1.30, P =.448). There was a statistically significant benefit on transfusion- and severe anemia-free survival compared with control ( HR = 0.59; P =.0097). Median Hb level increased with epoetin beta ( 11.7 g/dL at baseline to 13.3 g/dL at 24 weeks) but did not change with control ( 11.5 v 11.4 g/dL). Patients receiving epoetin beta experienced more thromboembolic events ( TEEs) compared with controls ( 13% v 6%; P =.012) with no difference in serious TEEs ( 4% v 3%). Epoetin beta did not significantly improve QoL in this study where patients had a high baseline Hb value. Conclusion In patients with MBC receiving chemotherapy and initial Hb less than 12.9 g/dL, epoetin beta increased Hb. No difference was detected in overall survival. Because of its superiority design, this study cannot, however, exclude clinically important differences in survival with absolute certainty.
引用
收藏
页码:592 / 598
页数:7
相关论文
共 26 条
[1]   Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer:: a meta-analysis [J].
Aapro, M. ;
Coiffier, B. ;
Dunst, J. ;
Osterborg, A. ;
Burger, H. U. .
BRITISH JOURNAL OF CANCER, 2006, 95 (11) :1467-1473
[2]  
ANTONADOU D, 2001, EJC SUPPL, V37, P144
[3]   Management of cancer-related anemia in patients with breast or gynecologic cancer:: New insights based on results from the European Cancer Anemia Survey [J].
Barrett-Lee, P ;
Bokemeyer, C ;
Gascón, P ;
Nortier, JWR ;
Schneider, M ;
Schrijvers, D ;
Van Belle, S .
ONCOLOGIST, 2005, 10 (09) :743-757
[4]   Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis [J].
Bohlius, J ;
Langensiepen, S ;
Schwarzer, G ;
Seidenfeld, J ;
Piper, M ;
Bennett, C ;
Engert, A .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) :489-498
[5]   Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients [J].
Bohlius, Julia ;
Wilson, Jayne ;
Seidenfeld, Jerome ;
Piper, Margaret ;
Schwarzer, Guido ;
Sandercock, Josie ;
Trelle, Sven ;
Weingart, Olaf ;
Bayliss, Sue ;
Djulbegovic, Benjamin ;
Bennett, Charles L. ;
Langensiepen, Simon ;
Hyde, Chris ;
Engert, Andreas .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10) :708-714
[6]   EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update [J].
Bokemeyer, C. ;
Aapro, M. S. ;
Courdi, A. ;
Foubert, J. ;
Link, H. ;
Osterborg, A. ;
Repetto, L. ;
Soubeyran, P. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (02) :258-270
[7]  
Boogaerts M, 2006, ANTICANCER RES, V26, P479
[8]  
Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO
[9]  
2-P
[10]   Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy [J].
Chang, J ;
Couture, F ;
Young, S ;
McWatters, KL ;
Lau, CY .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2597-2605